The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.
Lawmakers across the political divide have accused the pharma industry of abusing the patent system to keep the prices of their products as high as possible in a combative
Artificial intelligence (AI) is revolutionising industries. But with this exciting new frontier comes a complex challenge: protecting your intellectual property (IP).
The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qua
The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with San
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh